These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30689421)

  • 21. Response to the article "Sorafenib as a potential strategy for refractory pulmonary arterial hypertension".
    Weatherald J; Humbert M; Guignabert C; Montani D
    Pulm Pharmacol Ther; 2017 Aug; 45():11-12. PubMed ID: 28389260
    [No Abstract]   [Full Text] [Related]  

  • 22. Lung transplantation and atrial septostomy in pulmonary arterial hypertension.
    Norfolk SG; Lederer DJ; Tapson VF
    Clin Chest Med; 2013 Dec; 34(4):857-65. PubMed ID: 24267309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accelerometry: Improving Objective Assessments of Therapeutic Impact in Pediatric Pulmonary Arterial Hypertension.
    Austin ED; Feinstein JA
    Am J Respir Crit Care Med; 2017 Jul; 196(2):127-129. PubMed ID: 28707968
    [No Abstract]   [Full Text] [Related]  

  • 24. [The mechanisms of inflammation in pulmonary arterial hypertension.].
    Lu XL; He JG
    Zhonghua Jie He He Hu Xi Za Zhi; 2009 Nov; 32(11):862-5. PubMed ID: 20079299
    [No Abstract]   [Full Text] [Related]  

  • 25. Finding the Target: In Silico and Genetic Screening for Mechanistically Novel Drugs in Pulmonary Arterial Hypertension.
    Graham BB; Yu PB
    Am J Respir Crit Care Med; 2019 Jan; 199(1):9-11. PubMed ID: 30130137
    [No Abstract]   [Full Text] [Related]  

  • 26. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Mielniczuk LM; Swiston JR; Mehta S
    Can J Cardiol; 2014 Oct; 30(10):1233-40. PubMed ID: 25154043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [End tidal PCO(2) for evaluation of severity of disease in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension].
    Shi X; Yang GL; Chen Y; Guo J; Yang WL; Yuan P; Gong SG; Jiang R; Zhao QH; Wang L; He J; Chen TX; Liu JM
    Zhonghua Jie He He Hu Xi Za Zhi; 2017 Jan; 40(1):34-39. PubMed ID: 28100360
    [No Abstract]   [Full Text] [Related]  

  • 28. Response to the comment on the article entitled "Balloon atrial septostomy in pulmonary arterial hypertension: A beneficial effect on the control of rhythm abnormalities".
    Małaczyńska-Rajpold K
    Cardiol J; 2017; 24(4):457. PubMed ID: 28831784
    [No Abstract]   [Full Text] [Related]  

  • 29. Shear Stress Maladaptation in Pulmonary Arterial Hypertension. An Ageless Concept.
    Bonnet S; Provencher S
    Am J Respir Crit Care Med; 2016 Jun; 193(12):1331-2. PubMed ID: 27304240
    [No Abstract]   [Full Text] [Related]  

  • 30. Pulmonary arterial capacitance index is a strong predictor for adverse outcome in children with idiopathic and heritable pulmonary arterial hypertension: methodological issues to avoid misinterpretation.
    Ayubi E; Safiri S
    J Pediatr; 2017 May; 184():239-240. PubMed ID: 28434572
    [No Abstract]   [Full Text] [Related]  

  • 31. Therapeutic Value of ASK1 Inhibition in Pulmonary Arterial Hypertension.
    Boucherat O; Provencher S; Bonnet S
    Am J Respir Crit Care Med; 2018 Feb; 197(3):284-286. PubMed ID: 28930485
    [No Abstract]   [Full Text] [Related]  

  • 32. Comment on direct bilirubin as predictor of severity and mortality in idiopathic pulmonary arterial hypertension.
    Monneret D; Cracowski JL
    Int J Cardiol; 2017 Jul; 239():35. PubMed ID: 28560980
    [No Abstract]   [Full Text] [Related]  

  • 33. Expert Council resolution on pulmonary arterial hypertension (PAH) "Changing the paradigm of treating patients with pulmonary arterial hypertension".
    Chazova IE; Martynyuk TV
    Ter Arkh; 2019 Mar; 91(3):114-116. PubMed ID: 31094469
    [No Abstract]   [Full Text] [Related]  

  • 34. Reply to "Comment on direct bilirubin as predictor of severity and mortality in idiopathic pulmonary arterial hypertension".
    Xu XQ; Zhang HD; Jing ZC
    Int J Cardiol; 2017 Jul; 239():36. PubMed ID: 28560981
    [No Abstract]   [Full Text] [Related]  

  • 35. Multilevel omics: A next step on the way to understanding pulmonary arterial hypertension?
    Aman J; Hovingh GK
    Thorax; 2019 Apr; 74(4):317-318. PubMed ID: 30679265
    [No Abstract]   [Full Text] [Related]  

  • 36. Induced Pluripotent Stem Cells in Pulmonary Arterial Hypertension.
    Hamid R; Yan L
    Am J Respir Crit Care Med; 2017 Apr; 195(7):852-853. PubMed ID: 28362194
    [No Abstract]   [Full Text] [Related]  

  • 37. Myeloid Targets for Pulmonary Arterial Hypertension: Time for Another Look.
    Asosingh K; Farha S; Erzurum SC
    Am J Respir Crit Care Med; 2016 Aug; 194(3):384. PubMed ID: 27479064
    [No Abstract]   [Full Text] [Related]  

  • 38. Epidemiology of pulmonary arterial hypertension.
    Taichman DB; Mandel J
    Clin Chest Med; 2013 Dec; 34(4):619-37. PubMed ID: 24267294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk assessment in pulmonary arterial hypertension.
    Hoeper MM; Pittrow D; Opitz C; Gibbs JSR; Rosenkranz S; Grünig E; Olsson KM; Huscher D
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29599117
    [No Abstract]   [Full Text] [Related]  

  • 40. Expanded Drug Delivery Modalities in the Treatment of Pulmonary Arterial Hypertension.
    Brown LM
    Chest; 2016 Jul; 150(1):3-4. PubMed ID: 27396769
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.